IP Library › Granted Patent US 11,497,754
Granted Patent B2
US 11,497,754 · App. 16/782,406 · Granted Nov 15, 2022

Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions

Inventors: Douglas Covey (St. Louis, MO); Charles Zorumski (St. Louis, MO); Yukitoshi Izumi (St. Louis, MO); Makoto Ishikawa (St. Louis, MO)
Assignee: Washington University
A61K31/57A61K9/0019A61K9/0048A61K47/40A61P27/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,497,754
App. No.
16/782,406
Granted
Nov 15, 2022
Kind
B2
Abstract

The present disclosure is directed to a composition for prevention or treatment of neurodegenerative conditions. The composition comprises a neurosteroid, a synthetic enantiomer of a neurosteroid, or a combination thereof.

Claims (10)

1. A method of preventing or treating a neurodegenerative condition comprising inducing autophagy by administering an effective amount of a composition comprising a synthetic enantiomer of a neurosteroid, wherein the neurodegenerative condition is glaucoma and the synthetic entantiomer of the neurosteroid is ent-allopregnanolone.

2. The method of claim 1 , wherein the composition further comprises a saline solution.

3. The method of claim 1 , wherein administering an effective amount of the composition comprises administering the composition by intravitreal injection.

4. The method of claim 1 , wherein administering an effective amount of the composition comprises administering the composition by intracameral injection.

5. The method of claim 1 , wherein the synthetic enantiomer of the neurosteroid has a concentration of from about 10 nM to about 100 μM.

6. A method of attenuating pressure- induced retinal injury, the method comprising administering an effective amount of a composition comprising a synthetic enantiomer of a neurosteroid, wherein the injury is glaucoma and the synthetic entantiomer of the neurosteroid is ent-allopregnanolone.

7. The method of claim 6 , wherein the composition further comprises a saline solution.

8. The method of claim 6 , wherein administering an effective amount of the composition comprises administering the composition by intravitreal injection.

9. The method of claim 6 , wherein administering an effective amount of the composition comprises administering the composition by intracameral injection.

10. The method of claim 6 , wherein the synthetic enantiomer of the neurosteroid has a concentration of from about 10 nM to about 100 μM.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2020
From: COVEY, DOUGLAS; ZORUMSKI, CHARLES; IZUMI, YUKITOSHI; ISHIKAWA, MAKOTO
To: WASHINGTON UNIVERSITY
Reel/Frame 051794/0364 →
Continuity (2)
Provisional Application 62801187 · Feb 5, 2019
Related Publication 20200246356A1 · Aug 6, 2020
Cited By (1)
US 12,569,501